Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on androgenicity

I H Thorneycroft1

  • 1Department of Obstetrics and Gynecology, University of South Alabama, Mobile 36617, USA.

American Journal of Obstetrics and Gynecology
|February 13, 1999
PubMed
Summary
This summary is machine-generated.

Combination oral contraceptives effectively treat androgenic conditions like acne. Modern low-dose formulations are largely lipid neutral and do not increase atherosclerosis or myocardial infarction risk, except in heavy smokers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Yasmin: the reason why.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2003
Same author

Ultra-low-dose oral contraceptives: are they right for your patient?

Medscape women's health·2002
Same author

Protecting the endometrium. Opposing the hyperplasia/malignancy potential of ERT.

The Journal of reproductive medicine·2001
Same author

Vaginal bleeding patterns in women receiving hormone replacement therapy. Impact of various progestogen regimens.

The Journal of reproductive medicine·2001
Same author

Effect of low-dose oral contraceptives on androgenic markers and acne.

Contraception·2000
Same author

Analysis of in vitro migration patterns of human spermatozoa by a petri dish-based horizontal column.

Biology of reproduction·1999
Same journal

Likelihood ratios enhance clinical interpretation of metagenomic prediction of early-onset neonatal sepsis in preterm premature rupture of membranes (Letter-to-the-Editor).

American journal of obstetrics and gynecology·2026
Same journal

Taking risk stratification in preterm premature rupture of membranes to the bedside (Reply to Letter-to-the-Editor).

American journal of obstetrics and gynecology·2026
Same journal

Gestational Age at Full-Term Delivery and Long-Term Offspring Morbidity in Low-Risk Pregnancies: A Population-Based Cohort Study.

American journal of obstetrics and gynecology·2026
Same journal

Trajectories of childbirth-related posttraumatic stress symptoms after a vaginal delivery: a multicenter prospective study.

American journal of obstetrics and gynecology·2026
Same journal

Early life adversity and polycystic ovary syndrome among North American pregnancy planners.

American journal of obstetrics and gynecology·2026
Same journal

Survival assessment of adjuvant chemotherapy for cytology-negative, non-myoinvasive stage IC clear cell endometrial cancer.

American journal of obstetrics and gynecology·2026
See all related articles

Area of Science:

  • Reproductive endocrinology
  • Cardiovascular health
  • Dermatology

Background:

  • Newer progestins in combination oral contraceptives (COCs) are less androgenic, leading to misconceptions.
  • COCs are established treatments for androgenic conditions such as acne and hirsutism.

Purpose of the Study:

  • To clarify the benefits and risks of modern combination oral contraceptives, particularly regarding androgenic effects and cardiovascular health.
  • To address misconceptions about the lipid and atherosclerosis profiles of current low-dose COCs.

Main Methods:

  • Review of scientific literature on progestin androgenicity and COC effects.
  • Analysis of studies investigating lipid profiles, atherosclerosis rates, and myocardial infarction incidence in COC users.

Related Experiment Videos

Main Results:

  • All COCs are beneficial for androgenic conditions.
  • Older COCs had minor lipid effects; modern low-dose COCs are largely lipid neutral.
  • COC use is associated with reduced, not increased, atherosclerosis rates in human and animal studies.
  • Myocardial infarction risk is not elevated in COC users, barring heavy smoking.

Conclusions:

  • Combination oral contraceptives remain effective for treating androgenic conditions.
  • Current low-dose COCs demonstrate a favorable lipid and cardiovascular safety profile.
  • Misconceptions regarding the androgenic and cardiovascular risks of modern COCs are unwarranted for non-smoking users.